Aliment Pharmacol Ther 2011; 33: 291–303
Background Autoimmune pancreatitis is a steroid-responsive inflammatory pancreatic disease considered to be part of an immunoglobulin G4 (IgG4)-associated systemic disease.
Aim To review the management of autoimmune pancreatitis.
Methods We conducted a PubMed search using the following key words: autoimmune pancreatitis, IgG4-associated systemic disease, IgG4-associated cholangitis, diagnosis, natural history, treatment.
Results Although there are reports of spontaneous resolution of autoimmune pancreatitis, steroids have been shown to be effective in inducing remission, reducing the frequency of relapse and that of long-term unfavourable events compared to historical controls. There are no randomised data on autoimmune pancreatitis treatment. Oral steroids are used for induction of remission. Reported response results are excellent with variable proportions of patients achieving remission in different studies. After a period of 2–4 weeks, steroids are tapered and usually withdrawn within several months, although long-term maintenance therapy for all autoimmune pancreatitis patients has also been proposed. Disease relapse occurs in more than 40% of patients and can be effectively treated with additional immunosuppression, including azathioprine.
Conclusions Steroids are effective in inducing remission and in treating relapse in patients with autoimmune pancreatitis. Randomised trials on autoimmune pancreatitis therapy are lacking. To date, questions concerning the timing, choice and duration of long-term immunosuppression remain unanswered.
Autoimmune pancreatitis (AIP) is a steroid-responsive, fibroinflammatory pancreatic disease, which may be seen as part of a systemic disease involving a range of organs [immunoglobulin G4 (IgG4)-associated systemic disease].1–5 Although AIP was initially described more than 40 years ago,6 with the disease better defined by Japanese groups since 1995,7 it is only in the last 5 years that case series from USA and Europe have led to an acceptance that it is a global disease.8–10 Typical histopathological findings include a periductal lymphoplasmacytic infiltrate with storiform fibrosis, and obliterative phlebitis.3 The lymphoplasmacytic infiltrate in AIP has abundant IgG4-positive plasma cells on immunostaining (Figure 1)3, 11 and serum IgG4 levels are usually raised.5, 12 Although a response to steroid therapy is a consistently reported feature of AIP, management remains incompletely defined. In this article we report the evidence base for treatment, including indications, therapeutic regimens and the future direction of therapy.
An extensive PUBMED literature search was conducted using the terms ‘autoimmune pancreatitis’, ‘IgG4-associated systemic disease’, ‘IgG4-associated cholangitis’, ‘natural history’, ‘diagnosis’ and ‘treatment’. The results were combined with literature drawn from the reference lists of review articles yielded by this search as well as with data drawn from the authors’ published experience of AIP.
Patients with AIP are commonly male and over the age of 50 years8, 9, 13–16 but both sexes and all ages may be affected. Obstructive jaundice is present in 30–100% of cases,8, 9, 15–18 often in association with weight loss and abdominal pain. In view of imaging characteristically showing a low bile duct stricture in association with diffuse pancreatic enlargement (‘sausage pancreas’) or a focal mass,19 AIP has historically often been misdiagnosed as pancreatic cancer.20, 21 Patients may also present with features of pancreatic exocrine insufficiency.8 Although up to 65% of patients may present with new-onset mild abdominal pain,14–18 AIP differs from other forms of chronic pancreatitis in that severe intractable pain is unusual. Imaging may show a diffusely thin and abnormal pancreatic duct (Figure 2). Presentation with acute pancreatitis is rare, but can occur.22
Extrapancreatic disease is now recognised to occur in 40–90% of patients with AIP.8, 9, 23, 24 A similar lymphoplasmacytic infiltrate, containing IgG4 positive plasma cells, is seen within both pancreatic and extrapancreatic lesions.8, 11 Extrapancreatic sites and lesions include upper abdominal and/or mediastinal lymphadenopathy in up to 80% of cases,23 interstitial nephritis or other renal lesions in up to 45% of cases (often with rounded or wedge-shaped cortical lesions with decreased enhancement),9, 25, 26 retroperitoneal fibrosis in about 10% of patients,23, 25 and sialolacrimal disease and secondary Sjögren’s syndrome in 5–39% of cases.8, 23, 25 Lung, liver, pituitary and prostatic lesions have also been reported.27–31
Biliary disease is one of the most common extrapancreatic manifestations of AIP. Although the main cause of jaundice in AIP is obstruction at the level of the intrapancreatic portion of the common bile duct, associated with an inflammatory pancreatic head mass, stricturing in the rest of the biliary tree is increasingly recognised. This condition has been termed IgG4-associated cholangitis (IAC)32, 33 and has been reported to occur in 20–88% of cases of AIP.2, 8, 9, 23, 25, 34 Although differences in cholangiographic features have been reported between IAC and primary sclerosing cholangitis (PSC), with segmental strictures, long strictures with prestenotic dilatation and strictures of the common bile duct being more common in IAC,35 these distinctions can be subtle. A possible overlap between IAC and PSC is also suggested by the finding that 9–36% of patients with PSC have increased serum IgG4 levels compared with up to 1% in other liver diseases.36, 37 Of note, PSC patients with raised serum IgG4 levels have a more rapid progression to liver transplantation compared with those with normal levels.37
Two types of AIP have been described; lymphoplasmacytic sclerosing pancreatitis (type 1 AIP), in which the pancreas is involved as one part of a systemic IgG4-positive disease, and duct-centric (type 2 AIP), which is characterised by granulocyte epithelial lesions in the pancreas without IgG4 positive cells and without systemic involvement.38 It remains unclear whether these two types differ in terms of prognosis and should be managed in different ways, although clinical relapse after treatment appears to be less common with type 2 AIP. Patients with type 2 AIP are usually younger, have a lower prevalence of raised IgG4 levels, and more frequently have inflammatory bowel disease but less commonly other extrapancreatic manifestations compared to those with type 1 AIP.38 AIP type 2 cases are mainly described in series from Europe or the United States but are absent from Asian series.
There are no uniformly accepted diagnostic criteria for AIP, but several sets of criteria have been published, including the Asian diagnostic criteria for AIP proposed jointly by researchers in Japan and Korea,39 and the diagnostic criteria developed at the Mayo clinic.8 Both systems utilise imaging, serological and histopathological data as well as a response to steroids to diagnose AIP with the inclusion of extrapancreatic disease as a particular criterion in the latter system.8, 39 The HISORt criteria of the Mayo clinic, in which five cardinal features of AIP, histology, imaging, serology, other organ involvement and response to steroid therapy (HISORt) are taken into consideration, are outlined in Table 1 and the Asian diagnostic criteria for AIP are presented in Table 2. In our practice we use the Mayo clinic HISORt criteria to diagnose AIP. However, in a recent retrospective review of 26 consecutive patients treated for AIP in a single US centre, diagnostic criteria for AIP were fulfilled in only 22/26 cases (85%), whichever criteria were used.14 Although this may indicate reduced sensitivity of the Asian and HISORt criteria for the diagnosis of type 2 AIP (e.g. patients without other organ involvement or IgG4 increase), it also suggests that our understanding of the manifestations and complete spectrum of this disease is still evolving.14
|1. Histology||One or more of the following:|
(i) Pancreatic histology showing lymphoplasmacytic sclerosing pancreatitis
(ii) Lymphoplasmacytic infiltrate and storiform fibrosis with abundant (>10 cells/HPF) IgG4-positive cells in the pancreas
(i) Diffusely enlarged pancreas with delayed (rim) enhancement
(ii) Diffusely irregular, attenuated main pancreatic duct
(i) Focal pancreatic mass
(ii) Focal pancreatic duct stricture
(iv) Pancreatic atrophy
(v) Pancreatic calcification
|3. Serology||Raised serum IgG4 level|
|4. Other organ involvement||Hilar/intrahepatic biliary strictures, persistent distal biliary stricture, parotid/lacrimal gland involvement, mediastinal lymphadenopathy, retroperitoneal fibrosis|
|5. Response to steroid therapy||Resolution/marked improvement of pancreatic/extrapancreatic manifestation with steroid therapy|
|Diagnosis||Group A: diagnostic histology only|
Group B: typical imaging + serology
Group C: unexplained pancreatic disease with serology or other organ involvement (with abundant IgG4-positive cells) and response to steroid therapy
|1. Imaging||Both the following:|
(i) Diffuse/segmental/focal enlargement of the pancreas, occasionally with a mass and/or hypoattenuation rim
(ii) Diffuse/segmental/focal pancreatic ductal narrowing, often with bile duct stricturing
|2. Serology||At least one of the following:|
(i) High levels of serum IgG or IgG4
(ii) Detection of autoantibodies
|3. Histopathology||Pancreatic lymphoplasmacytic infiltration with fibrosis and abundant IgG4-positive plasma cells|
|Response to steroids (optional criterion)||Diagnostic trials of steroid therapy should be conducted carefully by pancreatologists and only in patients fulfilling criterion 1 with negative work-up for pancreaticobiliary cancer|
|Diagnosis||AIP should be diagnosed when criterion 1 and at least one of criteria 2 and 3 are satisfied, or when histology shows the presence of lymphoplasmacytic sclerosing pancreatitis in the resected pancreas|
In view of its presentation with obstructive jaundice and pancreatic enlargement, AIP frequently needs to be distinguished from pancreatic cancer. Two structured strategies have been described for this purpose, one from Japan40 and another from the United States.41 Both strategies rely mainly on imaging findings to stratify patients to receive treatment for AIP or pancreatic cancer, or to proceed to further diagnostic work-up. The Japanese strategy includes both CT and endoscopic retrograde pancreatogram (ERP) features, whereas the American strategy employs CT features alone to select patients for further cancer work-up, mainly by means of attempts to obtain a tissue diagnosis. As ERP features have been reported to have limited sensitivity to diagnose AIP in Western centres,42 in our practice, we use the American strategy (Figure 3). Further cancer work-up by means of brush cytology at ERCP and endoscopic ultrasound-guided fine-needle aspiration is required in patients with indeterminate imaging, i.e. with focally enlarged gland without features highly suggestive of cancer: low-density mass, pancreatic ductal dilatation, pancreatic duct cut-off, upstream pancreatic atrophy or liver lesions suggestive of metastases.41 Even in the event of negative cancer work-up, a pancreatic core biopsy, steroid trial or surgery (Figure 3) is required for diagnosis in approximately 30% of patients with AIP.41
Treatment of AIP
Is treatment necessary? An important observation related to AIP is that whilst a response to steroids is a criterion for diagnosing the disease, there are no prospective randomised placebo-controlled data related to steroid use. So are steroids of benefit, and do they ameliorate the disease?
The inflammatory process of IgG4-associated systemic disease typically responds to steroid treatment and this is also the case with AIP (Figure 4). Yet spontaneous resolution of symptoms, and of abnormal imaging (including the inflammatory pancreatic mass) are well described,13, 43 and occurred in 30% of cases in one AIP series.43 Kubota et al. performed a retrospective study on 20 patients with AIP, 12 of who improved on steroid treatment whereas the remaining eight patients improved spontaneously.44 Spontaneous remission was shown to be associated with normal IgG4 levels at diagnosis, the absence of obstructive jaundice, diabetes or oedema of the major papilla, negative immunostaining of papillary biopsies for IgG4-positive plasma cells and focal pancreatic swelling (P < 0.05 for all). In multivariate analysis, negative immunostaining of the duodenal papilla for IgG4-positive plasma cells was the only independent predictor of spontaneous remission of AIP [odds ratio (OR) 1.4, P = 0.03].44 This finding would need to be confirmed in larger prospective studies.
The effect of steroids on the natural history of AIP is largely unknown due to the lack of longitudinal placebo-controlled trials. However, a recent large retrospective study of 563 AIP patients in 17 Japanese centres showed that the remission rate was significantly higher (P < 0.0001) in the group of patients receiving steroids (451/459, 98%) compared to those who received only supportive care (77/104, 74%).45 Similarly, significantly fewer patients (P = 0.003) experienced a relapse among those who received steroids (110/451, 24%) compared to those who received only supportive care (32/77, 42%).45 Furthermore, Hirano et al. reported the results of a retrospective review of 42 AIP patients (of whom 19 were treated with steroids), aiming to determine the effect of steroids on the long-term outcome of AIP by comparing unfavourable events in patients treated with steroids with those in untreated historical controls.46 Unfavourable events were defined as the development of obstructive jaundice due to a distal biliary stricture, sclerosing cholangitis (i.e. IAC) with elevated liver enzymes, pancreatic pseudocyst or other extrapancreatic manifestations requiring treatment. At follow-up unfavourable events were significantly less frequent (P < 0.05) in the steroid treated group (6/19, 32%, mean follow-up 23 months) compared to controls (16/23, 70%, mean follow-up 25 months).46 In multivariate analysis, steroid therapy (OR 0.33, P = 0.029) and obstructive jaundice at presentation (OR 3.09, P = 0.026) were significant predictors of unfavourable events. The authors concluded that steroid therapy could reduce subsequent disease relapse and recommended early introduction of steroids particularly in patients presenting with obstructive jaundice.46
Steroid use as a diagnostic trial. As a response to steroids is a diagnostic criterion for AIP, should a trial of steroids be used to resolve diagnostic uncertainty (specifically between AIP and pancreatic cancer, the most important differential diagnosis)? This question was recently addressed in a study of 22 consecutive patients with atypical imaging for AIP, but without classical imaging criteria for pancreatic cancer.47 After a 2-week steroid trial, response to steroids was assessed on the basis of a marked improvement in pancreatic duct narrowing, and a reduction in size of the pancreatic mass. All patients who responded to steroids (15/22) were diagnosed as AIP after a median follow-up of 27 months, whereas all patients who did not respond to steroids (7/22) were diagnosed with pancreatic cancer, with a complete resection being possible in 6/6 patients who accepted surgery.47 Thus, a trial of steroids may be useful in supporting the diagnosis of AIP (without compromising the results of surgical therapy in the event of the diagnosis of pancreatic cancer being made), which reflects both the Asian and HISORt diagnostic criteria.8, 39 However, a steroid trial should not be given as a substitute for a thorough search for a definitive diagnosis, including relevant tissue sampling e.g. by means of endoscopic ultrasound-guided fine-needle aspiration. It should be performed only by pancreatology specialists and only in the context of a structured strategy to distinguish pancreatic cancer from AIP (Figure 3)40, 41 in which a multidisciplinary team of physicians, surgeons, radiologists and pathologists familiar with the two diseases is involved.48 It should be borne in mind that resolution of a pancreatic mass may occur coincidental to steroid therapy (e.g. focal acute pancreatitis), and that a steroid response may be seen in lymphoma of the pancreas, and even in pancreatic adenocarcinoma.47, 49, 50
Indications for treatment. There is no clear consensus as to which patients with a diagnosis of AIP should receive steroids. In series reported to date, the indications for steroid treatment have been obstructive jaundice (due to a distal common bile duct stricture and/or concomitant IAC) in 29–100% of cases,8, 9, 45, 51, 52 abdominal pain or other symptoms in 5–11%45, 52 and active extrapancreatic disease in 6–11%.8, 45 Although in some series, patients have received treatment solely on the basis of radiological, biochemical and/or serological findings8, 45, 52 it is unclear whether asymptomatic disease without active extrapancreatic involvement should be treated. Whilst a significantly raised serum IgG4 predicts extrapancreatic disease, and by association a subsequently more complicated course, with greater risk of poststeroid relapse, there is insufficient data to commence steroid therapy based upon the serum IgG4 per se.45, 52 In our practice, we treat patients with AIP and symptomatic disease, e.g. obstructive jaundice, abdominal pain, and/or the presence of symptomatic extrapancreatic disease, which is also in accordance with the Japanese guidelines for AIP.15 On the other hand we do not commence treatment based solely on radiological findings (i.e. in patients without obstructive jaundice or any other symptoms15, 46), or, for example, as an attempt to improve pancreatic exocrine function or glycaemic control in a patient with a ‘burnt out’ atrophic chronic pancreatitis due to AIP. Nevertheless, whilst the introduction of steroids during an early (predominantly inflammatory) phase of disease would be expected to be more successful than in patients with a longer duration of disease (likely to be more fibrosclerotic), favourable responses may sometimes be seen in longstanding disease, in particular with respect to extrapancreatic involvement. The indications for, and timing of, steroid treatment in AIP may change as our understanding of the effect of steroids on its natural history evolves.
Initial steroid treatment. As there are no randomised studies on the efficacy or dosing of steroids in AIP, steroid treatment of these patients is based mainly on case series and expert opinion. Although the use of parenteral steroids has been described in a case report,53 oral steroids have been used for induction of remission in all large AIP patient series.8, 9, 13, 14, 16, 45, 51, 52, 54–57 Different starting prednisolone doses have been used ranging from 5 mg to 60 mg once daily13, 16, 45, 52 but most clinicians in Japan, Korea, USA and UK use 30–40 mg daily.8, 9, 13, 14, 16, 45, 51, 52, 54, 56 Retrospective studies from Japan have shown that there is no correlation between the degree of morphological improvement on imaging and the initial prednisolone dose (30 mg/day vs. 40 mg/day)52 and that there is no difference in the period of time required to induce remission between an initial prednisolone dose of 30 mg/day and that of 40 mg/day (mean time 6.8 months vs. 6.3 months, P > 0.05).45 Thus, according to the data published to date, 30 mg of prednisolone once daily seems to be adequate as a starting dose for induction of remission in AIP, which is also in line with our clinical experience and practice.9, 56
Differing patterns of steroid tapering have been proposed. In Japan, prednisolone reduction is reported to begin after 2 weeks in 75% of cases, and after 3–4 weeks in 25%, and the dose is then reduced by 5 mg every 1–2 weeks.45 After reaching prednisolone 15 mg, the dose is reduced more slowly, by 2.5 mg to 5 mg every 2–8 weeks, until a maintenance dose of 2.5 mg to 5 mg/day is reached.45, 52 Tapering by 5 mg/week after an initial treatment period of 2–4 weeks has been generally reported from the UK and USA8, 9, 14, 56 with an attempt to withdraw steroids usually being made in all patients without an extended tapering period or maintenance therapy. All groups suggest close clinical follow-up, especially in the first months of treatment, with radiological, serological and biochemical evaluation as well as assessment of symptomatic relief.8, 9, 14, 45, 52, 56
Defining treatment response
Currently there are no generally accepted definitions of disease response and remission in terms of specific radiological, biochemical or serological variables that can be measured in an accurate and reproducible way and that are known to be reliable surrogates of long-term outcome. This is in part due to our limited knowledge of the natural history of AIP. Therefore, there is no consensus about the duration and the need of maintenance steroid therapy in AIP. Differences in definitions of remission and in steroid treatment regimens may account, at least in part, for the differences in reported frequency of disease remission on steroids among different series, ranging from 22% to 100% (Table 3). In one Japanese study, 22% of patients with AIP treated with steroids showed serological and morphological resolution after an average of 19.5 months of treatment and could be weaned off steroids, whereas 78% did not and required maintenance steroids.52 Similarly, in two other studies, 30% of patients were thought to have reached remission, as defined by near normalisation of cholangiopancreatography13, 54 and could be weaned off steroids after 21–37 months.13 The rest of the patients required maintenance treatment due to remaining biliary and/or pancreatic duct abnormalities13, 54 and/or for symptomatic control.13 In a recent retrospective Japanese study, complete remission was defined as the disappearance of clinical symptoms and resolution of the pancreatic and/or extrapancreatic manifestations on imaging.45 Remission was achieved in 98% of patients treated with steroids but 82% remained on maintenance therapy.45 The recently published Japanese guidelines on AIP acknowledge the lack of consensus on the length of steroid therapy, but suggest that maintenance therapy (prednisolone 2.5–5 mg daily) should be administered to all patients, with the aim of stopping treatment within 3 years, based on individual response.15 Most publications from Europe and USA report a shorter overall course of initial steroid treatment, ranging from 1.5 to 17 months.8, 9, 14, 56 This may reflect a number of factors, including the rapid improvement in symptoms, biochemical indices (Figure 5) and imaging (Figure 6) that occur within a few weeks in the majority of patients; the less common use of maintenance therapy from the outset of treatment; and the lack of requirement for complete normalisation of imaging in order to define remission. In our experience, marked improvement of biliary and pancreatic duct stricturing, but less frequently complete resolution, occurs following steroids, despite a complete symptomatic response. In a recent study from our group, disease response was defined as symptomatic, biochemical and radiological improvement following commencement of treatment, and disease remission as the maintenance of symptomatic, biochemical and radiological disease control after cessation of steroids and the removal of previously sited biliary stents.56 Of 28 patients with AIP treated with steroids, all had a disease response and 23 (82%) achieved remission and could stop steroids after a median of 5 months of treatment.56
|No. ofpatients||Response||Remission||Relapse||Average follow-up (months)|
|Kamisawa et al.54||10||100%||30%||0%||–|
|Kamisawa et al.13||10||100%||30%||0%||47.2|
|Nishino et al.51||12||100%||25%||33%*||41|
|Chari et al.8||17||100%||–||–||6.5|
|Ito et al.55||14||100%||100%||28%||–|
|Church et al.9||11||100%||–||54%†||18|
|Kamisawa et al.52||41||100%||22%||10%‡||43.5|
|Raina et al.14||19||100%||79%||68%§||9.7|
|Sandanayake et al.56||28||100%||82%||46%¶||26|
|Kamisawa et al.45||459||–||98%||24%**||–|
|Kawa et al.57||42||–||–||41%||72|
Whilst failure to normalise serum IgG4 may predict disease relapse45, 51 (see below), there is insufficient evidence to date to justify tailoring steroid therapy according to the level of serum IgG4, independent of other clinical parameters of disease activity. This may be particularly important in non-Asian patients with type 2 AIP whose serum IgG4 levels are less commonly elevated compared to type 1 AIP patients.
Additional initial management
Most patients with AIP present with obstructive jaundice, and should be considered for biliary drainage prior to commencing steroid therapy, particularly where there is diagnostic uncertainty. Endoscopic retrograde cholangiopancreatography (ERCP) may demonstrate the biliary features of IAC or characteristic pancreatic duct changes.58 It also allows biliary cytology to be taken (to help to exclude malignancy), and ampullary biopsies to identify an IgG4 positive lymphoplasmacytic infiltrate that may be present (Figure 1).59 In the event of diagnostic uncertainty, sampling by means of endoscopic ultrasound-guided fine-needle aspiration should also be undertaken in the context of a structured strategy to exclude pancreatic malignancy (Figure 3). In published series, 14–64% of AIP patients underwent transhepatic or endoscopic biliary drainage prior to steroid therapy.9, 14, 51, 52, 54, 55 Where there is no diagnostic doubt about AIP, ERCP may not be necessary prior to steroids in all cases. The risks of post-ERCP pancreatitis and biliary colonisation may be avoided, but this needs to be balanced against the potential septic risks of introducing steroids in the setting of unrelieved biliary obstruction.
Diabetes mellitus is common in AIP, and requires management. In a recent large retrospective study, diabetes mellitus was present in 143 of 459 (31%) AIP patients prior to steroid treatment, and blood glucose levels were controlled with insulin in 73% and with oral hypoglycaemic agents in 27% of cases.45 Although improvement in diabetic control following the introduction of steroids for AIP has been reported,13, 51, 52, 55, 60, 61 we have seen this infrequently in our practice. Nevertheless, glycaemic levels need to be monitored during steroid therapy and treatment instituted or adjusted as appropriate. Exocrine pancreatic dysfunction is also frequent in AIP, occurring in up to 88% of patients in some series.51, 55, 60 Thus, we routinely measure pancreatic faecal elastase levels in these patients and prescribe pancreatic enzyme supplements as necessary. Pancreatic exocrine function may improve after steroid therapy in up to 2/3 of patients51, 55, 60 although worsening has also been reported poststeroids.55 In our patient group, presteroid pancreatic insufficiency persisted in most patients despite steroids and despite overall clinical improvement.62
Early reports emphasised the predictable and gratifying response to steroid therapy in patients with AIP.63–65 Over recent years disease relapse following steroids has become increasingly recognised, with series reporting its frequency ranging from 0% to 68% (Table 3). This variability may reflect differences between clinical groups with respect to the definition of relapse, the length of clinical follow-up, and perhaps the use or not of very slow tapering regimens or maintenance therapy. In a large patient series, relapse of AIP was defined as reappearance of symptoms with the development or reappearance of pancreatic and/or extrapancreatic abnormalities and/or marked elevation of serum IgG or IgG4 levels.45 In this study relapse occurred in 24% of patients treated with steroids.45 We have recently defined relapse as recurrence of disease activity after achievement of remission and cessation of steroids, and discriminated it from failed weaning of steroids; the latter being defined by a flare of disease activity whilst tapering initial steroid course, or an inability to wean steroids completely due to biochemical and/or radiological deterioration.56 According to our experience failure to wean steroids occurs in 18% of patients treated with prednisolone and disease relapse in 35% of patients achieving remission.56 In type 2 AIP patients, in whom IgG4 levels may not be elevated,38 serum IgG4 may be less important in defining relapse and, thus, we do not define relapse in terms of serum IgG4 in isolation. Instead we rely mainly on imaging findings (e.g. pancreatic enlargement and/or reappearance of extrapancreatic lesions on follow-up imaging) and/or biochemistry.56
Disease relapse may involve the pancreas in up to 52% of cases.45 Although the absence of pancreatic stones was initially reported to be a characteristic feature of AIP,7 it has recently been shown that pancreatic stones may be formed in the course of the disease and that they occur more commonly in patients experiencing disease relapse.52, 57, 66, 67 The fact that pancreatic stones may occur in AIP and that 7–12% of patients with chronic pancreatitis have raised levels of IgG468, 69 suggest that AIP may be a cause of ‘idiopathic chronic pancreatitis’.57 Disease relapse appears to be particularly common in extrapancreatic sites, especially the biliary tree, and has been reported in 48–100% of cases (Table 3). The reason for this is unclear but it may suggest that pancreatic fibrosis is established early in the course of AIP, which is in line with the frequent observation of pancreatic atrophy (and exocrine insufficiency) following steroid therapy, despite its introduction soon after clinical presentation.8, 9, 51, 52, 54 The fact that disease relapse commonly occurs outside the pancreas further supports the concept of IgG4-associated systemic disease, with the pancreas being one of the organs involved.1–5 It also suggests that immunosuppression for AIP should focus not only on the pancreas, but also on extrapancreatic disease. Disease activity may vary significantly in different organs at any single time point, and control of disease in one organ in response to treatment may not be reflected in another.56
Certain factors have been reported to predict relapse in patients with AIP. In a series of 20 AIP patients, raised serum IgG4, diffuse pancreatic enlargement, and the presence of a lower bile duct stricture were found to be significantly associated with a relapse of AIP.44 However, after multivariate analysis only diffuse pancreatic enlargement was found to be an independent predictor of relapse (OR 26.2, P = 0.03).44 In a study from our group, 54% of patients with AIP who also had IgG4-associated cholangitis subsequently relapsed or failed to wean steroids compared to all AIP patients without IgG4-associated cholangitis who achieved and maintained remission.56 Serum IgG4 levels fall in response to steroids12, 51, 52, 54 and persistently raised serum IgG4 may be associated with relapse45, 51 and failure of disease control with steroids.54 However, serum IgG4 levels have also been reported to fluctuate by more than 3 g/L in patients under maintenance therapy45 and data confirming the value of serum IgG4 in predicting relapse are not unanimous in the literature.56 Several other factors have been reported to be related to disease relapse, including immune complex formation,68 consumption of the complement factors C3 and C4,70 raised liver function tests9 and specific HLA71 and cytotoxic T-lymphocyte antigen 4 polymorphisms.72 To date, it is unclear whether it is possible to reliably identify patients who may experience early relapse based on any of these parameters as their operating characteristics for relapse prediction have not been fully defined.
In a large retrospective study by Weber et al. approximately 3% of patients undergoing pancreatic resection for presumed pancreatic cancer are subsequently diagnosed with AIP.73 In this study, 1287 patients who had undergone pancreaticoduodenectomies mainly for presumed pancreatic malignancy were included. Eight out of 29 patients (28%) diagnosed with AIP following surgery developed relapse after a median of 11 months post-operatively (median follow-up 38 months). Seven out of eight patients had jaundice and were shown to have biliary strictures on cholangiography.73 Relapse occurred faster in the group of patients undergoing distal pancreatectomy compared to those undergoing pancreaticoduodenectomy. The authors concluded that close follow-up is mandatory for all patients diagnosed with AIP following pancreatic resection.73 This work emphasises that not only can a misdiagnosis of pancreatic cancer in patients with AIP lead to high-risk, unnecessary surgery, but also that this surgery may frequently not ‘cure’ the disease.
Management of relapse
Published data on management of disease relapse in AIP are scarce and randomised trials are again lacking. Most Japanese groups report treatment of relapse with a further course of steroids,45, 51, 52 often commencing at prednisolone 30–40 mg per day.45 According to the Japanese guidelines for AIP,15 steroids need to be tapered more gradually after a relapse (by 1 mg every 2 weeks),51 with 97–100% of patients responding to this approach.45 In the USA and the UK relapse is commonly treated with further steroids and the introduction of azathioprine.8, 9, 14, 56 We have reported on the successful reintroduction of prednisolone 30 mg per day and azathioprine 1 mg/kg per day, increasing to a target dose of 2 mg/kg per day.56 Pancreatitis is a known side-effect of azathioprine, occurring in approximately 2% of cases of azathioprine use (usually mild),74, 75 but there is no evidence that this risk is increased in AIP. Steroid therapy is tailored to clinical, biochemical and radiological response, with the majority of patients being able to cease their steroid course within 3–9 months in our series.56 It is uncertain how long treatment following relapse should be continued, but the lesson of managing autoimmune hepatitis,76 that cessation of azathioprine should not be considered for 3 years, even in the setting of disease control, may be appropriate. Similarly, some patients may require the maintenance of low-dose prednisolone (2.5–5 mg per day) whilst on azathioprine, as is advocated in some patients with autoimmune hepatitis.76
Should prolonged maintenance therapy be commenced at the outset of treatment?
Maintenance therapy from the outset has been proposed in the Japanese guidelines for AIP,15 as it has been reported to correlate with lower relapse rates (23% compared to 34% in patients who stopped maintenance therapy, P = 0.048).45 An analogy with the management of autoimmune hepatitis again seems relevant, as both conditions are steroid-responsive and show high relapse rates that may necessitate long-term immunosuppressive treatment. Azathioprine monotherapy is effective for long-term maintenance of remission in autoimmune hepatitis.76 However, disease relapse occurs in virtually all patients with autoimmune hepatitis who stop immunosuppression early77 whereas relapse of AIP following steroid therapy is frequent (Table 3), but does not seem to be universal. Thus, to date, we believe that there is insufficient data to suggest long-term maintenance therapy from the outset in all AIP patients. Nevertheless, further studies may help to define subgroups that carry a very high-risk of relapse, such that long-term immunosuppression needs to be considered from diagnosis.
Alternative immunosuppressive agents
Long-term immunosuppression with steroids is effective in maintaining remission and treating relapse and it is proposed in the recent Japanese guidelines for AIP.15 However, potential side effects of steroid therapy, such as osteoporosis and worse glucose tolerance, raise the issue of whether alternative drugs could be used. Apart from azathioprine, several other agents, including methotrexate,14 mycophenolate mofetil,33 cytoxan33 and rituximab78, 79 have been used, most in small numbers of patients. It is currently unknown whether long-term immunosuppression may alter the natural history of AIP or whether any of these agents has an advantage over long-term steroid monotherapy.
Although randomised placebo-controlled trial data to support the initial use of steroid therapy are absent, it is very unlikely that such a study can now be performed, due to the extensive data suggesting benefit. More feasible may be trials comparing treatment strategies (e.g. initial limited steroid course vs. long-term maintenance from the outset), or specific therapies (e.g. low-dose steroids vs. azathioprine for maintenance). A better understanding of the natural history of AIP would allow new endpoints for such trials to be defined, with a focus on the prevention of irreversible organ dysfunction (both pancreatic and extrapancreatic). In particular, the identification of patients with AIP who need long-term maintenance treatment as well as the timing, choice and duration of immunosuppression in AIP warrant further study.
Declaration of personal and funding interests: None.